feedback

Course Director

Paul Richardson, MD
Paul Richardson, MD

RJ Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader, Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Faculty

Faith E. Davies
Faith E. Davies, MBBCh, MRCP, MD, FRCPath

Professor of Medicine
Myeloma Institute
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Accredited by

The Medical College of Wisconsin

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2018-Apr-13
Expiration Date:2019-Apr-12
Estimated Time for Completion:1 hour
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

This PeerView activity, based on a recent live symposium held at the 2018 BMT Tandem Meetings, offers expert insights on the continued integration of next-generation and novel therapeutics in conjunction with the use of autologous hematopoietic stem cell transplant (HCT), while also exploring the clinical implications of new data for the selection of newer induction, post-HCT maintenance, and salvage regimens across the breadth of myeloma treatment settings. Our panel of myeloma experts also assesses other issues in transplant-eligible myeloma patients, including early versus late HCT, the growing importance of minimal residual disease (MRD) assessment, and the emergence of new agent classes and therapeutic concepts for heavily pretreated individuals, including those who have had HCT as part of their treatment history.

Upon completion of this activity, participants should be better able to:
  • Summarize evidence regarding the current role and clinical criteria for the use of emerging and established regimens in conjunction with autologous stem cell transplantation (ASCT) in the management of multiple myeloma
  • Develop personalized induction and post–ASCT maintenance/consolidation regimens with novel components for eligible patients with multiple myeloma
  • Select novel therapeutics for the management of relapsed multiple myeloma post-ASCT

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the management of patients with multiple myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: April 13, 2018 - April 12, 2019
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Paul Richardson, MD
RJ Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader, Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Paul Richardson, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Celgene Corporation and Takeda Pharmaceuticals U.S.A., Inc.
Advisory Board for Celgene Corporation; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Faith E. Davies, MBBCh, MRCP, MD, FRCPath
Professor of Medicine
Myeloma Institute
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Faith E. Davies, MBBCh, MRCP, MD, FRCPath, has a financial interest/relationship or affiliation in the form of:
Consultant for Celgene Corporation; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:

The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Providership


This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Adaptive Biotechnologies, Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics, Inc., Sanofi Genzyme, and Takeda Oncology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.